

## Hans-Heinrich Reckeweg Award

### Conditions of Entry

#### 1. Preliminary information

Through these awards, *Biologische Heilmittel Heel GmbH* supports the further development of antihomotoxic medicine and thus continues its long-established promotion of this particular therapeutic approach.

#### 2. Award names

The main award is offered as the "Hans-Heinrich Reckeweg Award" meant for outstanding research projects in the field of Homotoxicology. The second award is known as the "Hans-Heinrich Reckeweg Incentive Award".

#### 3. Sponsorship

The prizes are awarded under the auspices of the Scientific Advisory Board of *Biologische Heilmittel Heel GmbH*.

#### 4. Awarding of the winners and prize monies

The prizes are awarded annually. The Hans-Heinrich Reckeweg Main Award is endowed with € 10,000, the Hans-Heinrich Reckeweg Incentive Award with € 5,000. The awards may also be shared.

#### 5. Award criteria

##### 5a. Main award

The prize will be awarded for new and so far unpublished completed scientific works of fundamental theoretical and/or practical significance for complex homeopathy (antihomotoxic medicine) in the following areas:

- Fundamental contribution to the scientific justification of complex homeopathy (antihomotoxic medicine)
- Practical application of homeopathic combination preparation therapy (antihomotoxic therapy) in the clinic and/or practice (human medicine)
- Therapeutic work in the field of biological veterinary medicine (no research involving animal testing).

##### 5b. Incentive award

The prize will be awarded for results arising from clinical, practical or fundamental research that invite further investigation. Otherwise, the same criteria apply as cited in 5a.

Appendix 1 details the criteria that are used to assess the studies submitted. Appendices 2 and 3 contain recommendations regarding the planning of scientific studies into the practical application of antihomotoxic therapy.

## 6. Submission of studies

Authors must submit two manuscripts, written either in German or English (standard English), in a form suitable for publication. The requirements are set out in the manuscript guidelines (Appendix 4). Each submitted work must be accompanied by the following:

- A declaration on the word of honour of all named authors that they are the sole originators of the submitted work (Appendix 5)
- The agreement of all named authors that they accept as binding the regulations governing the award of the Hans-Heinrich Reckeweg Awards and that they will abide by them irrevocably (Appendix 6).

## 7. Deadline for submissions

The deadline for submissions is May 31<sup>st</sup> every year. The work must have been submitted to the headquarters of *Biologische Heilmittel Heel GmbH* by that date. The date of posting applies.

Biologische Heilmittel Heel GmbH  
Dr.-Reckeweg-Str. 2-4  
76532 Baden-Baden  
Germany

## 8. Jury

The jury consists of the current members of the *SAB research working group*. (*SAB: Scientific Advisory Board of Heel*).

The jury retains the right to allocate work submitted to either of the two awards.

## 9. Exclusion of legal redress

The jury's decision is binding for all participants and is final.

## 10. Notification of award winners

Each award winner will be notified of the jury's decision in writing by *Biologische Heilmittel Heel GmbH*. The announcement will be made in mid-September of the respective year.

## 11. Presentation of the award

The award will be presented during the Medical Week (Medizinische Woche) in Baden-Baden, Germany.

## 12. Ownership and copyright

*Biologische Heilmittel Heel GmbH* has unrestricted right of disposition over all manuscripts submitted. Copyright is retained by the author. The company is entitled to inform the press about the presentation of the award and the award winner(s).

## 13. Reservation of the right to change

The company reserves the express right to change these conditions of entry as applicable to future awards.

## Evaluation Criteria

<b>1.</b>	<b>POINTS RELATING TO THE TEXT</b>
<b>1.1</b>	<b>Question addressed/subject matter</b>
1.1.1	Is the question addressed significant for the scientific justification/ application of antihomotoxic medicine?
1.1.2	Is the question addressed/subject matter original/innovative?
1.1.3	Is the question addressed/subject matter of current interest?
<b>1.2</b>	<b>Results/Methods</b>
1.2.1	Do the methods described conform to the current standard?
1.2.2	Are the methods used appropriate to the question addressed?
1.2.3	Is the question addressed answered satisfactorily by the results which are presented?
1.2.4	Are the statements of therapeutic/fundamental relevance?
<b>2.</b>	<b>FORMAL CRITERIA</b>
<b>2.1</b>	<b>Is the question addressed formulated in an understandable manner?</b>
<b>2.2</b>	<b>Are the results presented in an understandable manner? (figures, tables, text)</b>
<b>2.3</b>	<b>Are the methods used described in an understandable manner?</b>
<b>2.4</b>	<b>Are the references current, correctly cited and sufficient?</b>


## Checklist for Planning a Scientific Investigation

The aim of this checklist is to provide assistance when planning a scientific investigation into the application (e.g. clinical studies, practical studies, case reports) of antihomotoxic therapy in practice (human and veterinary medicine):

- Medical/scientific background of the investigation, indicate how and why the investigation adds to the existing knowledge of anti-homotoxic medicine.
- Aim(s) of the investigation
- Relevant target parameters
- Selection and justification of study design (e.g. comparator/placebo, open/blind)
- Type of randomisation (where relevant)
- Inclusion and exclusion criteria of patients
- Description of patient population (incl. number of patients, age, sex, vital parameters, risk factors)
- Case histories (homeopathic, clinical)
- Diagnostic procedures
- Diagnosis/ses
- Selection of study medication (test substance, comparator, placebo), form of administration, dosage, and type of application
- Accompanying disease(s), supportive therapies
- Time structure of therapy (incl. schedule, time-scale)
- Length of treatment / observation
- Criteria for terminating treatment
- Recording unwanted phenomena / effects of medication
- Criteria for evaluating the efficacy of the therapy / medication
- Criteria for evaluating medication tolerance
- Criteria for evaluating patient compliance
- Statistical methods used

# Flow Chart

(Only to be filled out for randomised clinical studies)



Sequence of a clinical study based on treatment and observation. Number of patients with terminated treatment / incomplete observation. Point at which primary and secondary target values determined.

**R** stands for randomisation, (n=...) stands for number of patients stated.

## Manuscript Guidelines

Heading	Subheading	Description
<b>Title page</b>		<p><b>The title page must contain the following:</b></p> <ul style="list-style-type: none"> <li>• Title and abbreviated title of the article</li> <li>• Full name of each author and the institute/practice to which they belong</li> <li>• Postal address of the corresponding author, including phone, fax and e-mail details</li> <li>• Any acknowledgements and indications of sponsors</li> </ul>
<b>Summary</b>		<p><b>Structured form (maximum 250 words)</b></p> <ul style="list-style-type: none"> <li>• Background</li> <li>• Reason for the study</li> <li>• Materials and methods</li> <li>• Results</li> <li>• Conclusions</li> <li>• 3 – 5 key words</li> </ul>
<b>Text structure</b>		<p><b>Studies are usually – though not necessarily – arranged in paragraphs with the following headings</b></p> <ul style="list-style-type: none"> <li>• Introduction</li> <li>• Methods</li> <li>• Results</li> <li>• Discussion</li> </ul> <p>Any long sections should be subdivided with appropriate subheadings.</p>
<b>Introduction</b>		<p><b>Details</b></p> <ul style="list-style-type: none"> <li>• The medical/scientific basis/background to the study</li> <li>• Any a priori study hypotheses</li> <li>• The clinical aims of the study</li> </ul>
<b>Methods</b>	Study structure	<p><b>Describes</b></p> <ul style="list-style-type: none"> <li>• The relevant legal requirements</li> <li>• The planned test populations and any inclusion/exclusion criteria</li> <li>• The study design</li> <li>• The treatments planned and their schedule</li> <li>• The primary and secondary target values</li> <li>• The number of patients or size of group(s)</li> <li>• The statistical methods used</li> <li>• Pre-defined termination criteria (where relevant)</li> </ul>
	Patient classification	<p><b>Describes</b></p> <ul style="list-style-type: none"> <li>• Treatment groups</li> <li>• Randomisation (where relevant)</li> <li>• Procedures used to assign patients to the different groups</li> </ul>
	Masking of treatment (in the case of blind investigations)	<p><b>Describes</b></p> <ul style="list-style-type: none"> <li>• The form of administration, e.g. capsules, tablets</li> </ul> <p>The similarity between the test and the comparative treatment (e.g. appearance, taste)</p>

## Manuscript Guidelines (continued)

Heading	Subheading	Description
<b>Results</b>	Course of treatment and post-treatment observation	<p><b>Describes</b></p> <ul style="list-style-type: none"> <li>• The route taken by patients through the study</li> <li>• At what point which treatment measures were carried out</li> <li>• At what point which target values were ascertained, giving breakdowns for each group and with details of case numbers (in the case of randomised studies see Appendix 3)</li> </ul>
	Evaluation	<ul style="list-style-type: none"> <li>• Presentation of results (text, tables, and illustrations) and evaluation of the therapy's impact on the primary/secondary target values</li> <li>• Where possible, results should be given in absolute numbers, e.g. 10/20, rather than 50%</li> <li>• Description of all deviations from the study plan (as originally planned) and the reasons involved</li> <li>• Description and evaluation of unwanted phenomena</li> </ul>
<b>Discussion</b>		<ul style="list-style-type: none"> <li>• Specific interpretation of study results (including their clinical relevance)</li> <li>• General interpretation of results taking into account the whole body of available evidence (not forgetting the latest publications!)</li> </ul>
<b>References</b>		<ul style="list-style-type: none"> <li>• Only publications cited in the text are to be listed (in numerical or alphabetical order) in the bibliography – 20 sources maximum.</li> </ul>
<b>Tables and illustrations</b>		<ul style="list-style-type: none"> <li>• Each table must be submitted double-spaced on a separate page. Tables and figures are to be numbered consecutively in the order in which they (first) appear in the text and given a comprehensible legend. It must be ensured that every table and figure is cited in the text.</li> <li>• Figures and legends will be handled separately, and all legends should thus be submitted on a separate page. If it is not clear how a figure should be looked at, this is to be indicated by "above/below", or "right/left". Each figure must be numbered.</li> <li>• Photos of persons: identification of the person depicted should not be possible, unless the photos are submitted together with written permission to print from the person(s) depicted.</li> </ul>

## Declaration on the word of honour of the author(s)

(Please sign and submit together with the manuscript!)

Title of the work:

---

---

---

---

Author(s)/academic title(s):

---

---

Institute:

---

---

---

I hereby declare that I was significantly involved in the planning and performance of the enclosed study, the evaluation of the results and the preparation of the manuscript and that I take full responsibility for it. I have checked the final version of the submitted manuscript and agree to its publication.

I confirm that the enclosed manuscript or a manuscript of "very similar content" has not yet been published by or submitted to another journal and has not been accepted for publication elsewhere. If requested by the jury, I will make available for scrutiny the data on which this study is based.

Signature(s) of the author(s):

Date:

---

---

---

## Declaration of Consent

(Please sign and submit together with the manuscript!)

I hereby accept as binding the rules applying to the award of the  
Hans-Heinrich Reckeweg Award:

*Biologische Heilmittel Heel GmbH* has unrestricted right of disposition over  
the manuscript submitted. The company is entitled to inform the press  
about the presentation of the award, the award winner(s) and all studies  
submitted for the award. Copyright is retained by the author(s).

Signature(s) of the author(s):

Date:

---

---

---

---